Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Sepsis 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Febrile Neutropenia 1

Interventions

Cyclophosphamide 217fludarabine phosphate 120Rituximab 108Filgrastim 100Peripheral Blood Stem Cell Transplantation 86Etoposide 83fludarabine 80Busulfan 80Radiotherapy 76Tacrolimus 73Methotrexate 73Melphalan 71Mycophenolic Acid 70Cytarabine 65Antilymphocyte Serum 61Whole-Body Irradiation 56Cyclosporine 54Vincristine 49Prednisone 42Doxorubicin 41Methylprednisolone 34Granulocyte Colony-Stimulating Factor 34Dexamethasone 30Cord Blood Stem Cell Transplantation 29sargramostim 27Alemtuzumab 26Stem Cell Transplantation 24Carmustine 24Thiotepa 23thymoglobulin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Anti-Bacterial Agents × Other hematologic neoplasm × Clear all
NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
19 enrolled 18 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡